New combo therapy shows promise for tough lymphoma cases
NCT ID NCT03210662
First seen Jan 13, 2026 · Last updated Apr 24, 2026 · Updated 19 times
Summary
This study tested a combination of the immunotherapy drug pembrolizumab and targeted radiation in 17 patients with non-Hodgkin lymphoma that had returned or stopped responding to treatment. The goal was to see if adding radiation could help the immune system fight the cancer better than the drug alone. The trial focused on measuring how many patients' tumors shrank or disappeared after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT T-CELL NON-HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.